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use antibiotics reasonably has become an urgent problem
to be solved. 
OBJECTIVE: The purpose of this study was to evaluate
the efficacy and cost of ceftriaxone, cefotaxime, and ce-
furoxime therapy in patients with moderate lower respi-
ratory tract infection. 
METHODS: 150 patients with moderate lower respira-
tory tract infection were randomized to receive ceftriax-
one (1g .d), cefotaxime (1g b.i.d), and cefuroxime (0.75g
t.i.d). Evaluation of clinical efficacy depended on
whether or not clinical findings subsiding eradication of
the initially susceptible and normal outcome of labora-
tory tests were obtained 7 days after therapy. In the cost
analysis we have taken the following costs into account:
drug cost, check-up cost, bed cost, administration cost,
treatment of adverse events, and lost income of patients. 
RESULTS: 107 patients were analyzed. The effectiveness
rates of ceftriaxone, cefotaxime, and cefuroxime arms
are 86.21 (25/29), 85.37 (35/41), and 75.68% (31/38),
respectively, with no significant difference (p  0.05),
but their costs are 2931.97  161.84, 3749.52 
215.98, and 3340.56  221.26 yuan (RMB), respec-
tively, with significant difference (p  0.05).
CONCLUSION: Our pharmacoeconomic analysis dem-
onstrated that of all the three drugs ceftriaxone had the
best cost-effectiveness, and was a better choice for the
treatment of moderate lower respiratory tract infection.
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OBJECTIVE: A prevention effectiveness analysis frame-
work was used to estimate the cost-effectiveness of a tu-
berculosis prevention program compared to no program
along the US/Mexico border. The prevention program
used prophylactic isoniazid therapy in patients who
tested positive for tuberculosis infection. This analysis
evaluated the cost-effectiveness of the tuberculosis pre-
vention from the county government perspective and was
modeled over two time periods, 5 and 15 years post-pre-
ventive therapy initiation. 
METHODS: The outcome of interest, cases of active tu-
berculosis averted, was calculated through a Monte Carlo
simulated Markov process model. Costs were calculated
using hospital discharge and actual tuberculosis preven-
tion and active treatment program data. Average and in-
cremental cost-effectiveness ratios were calculated for the
tuberculosis prevention program scenario. Cost-effective-
ness ratios were calculated separately with the inclusion
or exclusion of the tuberculosis contagion costs. 
RESULTS: The results indicate that the tuberculosis pre-
vention program provides cost-savings to the county.
Baseline incremental cost-effectiveness ratios, for the 5
and 15 year analyses, demonstrated substantial cost sav-
ings ($1023 and $4971 per case averted, respec-
tively). Sensitivity analyses were performed across key
transitional probabilities and discount rates. Results of
sensitivity analyses indicate that as the rate of hospital-
ization for tuberculosis decreased and compliance with
the preventive therapy decreased, cost-effectiveness ratios
increased to $2015 and $877 per case averted, respec-
tively, for the 5-year preventive treatment scenario. How-
ever, when the tuberculosis contagion consequences of
not having the tuberculosis prevention program were
considered, the cost-effectiveness and cost-savings were
once again realized. 
CONCLUSION: The results indicate that rather than in-
curring costs to avert active tuberculosis cases, having the
tuberculosis prevention program results in cost-savings.
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Influenza is a common disease that is often perceived as
self-limiting and mainly treated at home. However, for a
portion of influenza sufferers the disease may warrant a
visit to the emergency room (ER) or hospitalization. 
OBJECTIVE: The purpose of this study is to estimate the
resources consumed and associated costs of treating in-
fluenza patients in the ER and hospital. 
METHODS: Patient-level clinic and cost data were mea-
sured for the study population identified in the Premier
Decision Support Services (DSS) databases. Data were
analyzed retrospectively from January 1, 1997 to June
30, 1998 for patients with a diagnosis code for influenza
using International Classification of Diseases, Ninth Re-
vision-Clinical Modification (ICD-9) coding. Individual
medication data were collected for a subset of the sub-
jects in 1997 and all subjects in 1998. Data were summa-
rized using means (SE) and multivariate analyses of
variance (  0.05) were performed to determine if ob-
served differences in mean costs across demographic vari-
ables were statistically significant. 
RESULTS: Of the 1362 patients who met inclusion crite-
ria, 333 (24.4%) required an inpatient hospital stay for
influenza. The average total cost and charge per patient
for ER only visits were approximately $142 and $218,
respectively. The average total cost and charge per hospi-
talized patient were approximately $3251 and $5938, re-
spectively. Other cost and demographic data are further
detailed in the study. 
